Aripiprazole versus olanzapine in the treatment of schizophrenia: A clinical study from India

International Journal of Psychiatry in Clinical Practice

Volumn 17, Issue 1, 2013, Pages 21-29

  Jindal, K C ^a   Singh, Gurvinder Pal ^a,b   Munjal, Vivek ^a  

^a GGS Medical College & Hospital Faridkot   (India)

^b Department of Psychiatry ^*  (India)

Author keywords

Aripiprazole; Olanzapine; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; LORAZEPAM; OLANZAPINE; TRIHEXYPHENIDYL;

ADULT; AGED; AKATHISIA; AMENORRHEA; ARTICLE; ASTHENIA; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; ICD-10; INDIA; KIDNEY FUNCTION TEST; LABORATORY TEST; LASSITUDE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; SIMPSON ANGUS SCALE; SLEEP TIME; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UKU SIDE EFFECT RATING SCALE; VOMITING; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873660725     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2011.653376     Document Type: Article

References (31)

1. Burton S. Symptom domains of schizophrenia: the role of atypical antipsychotic agents. J Psychopharmacol 2006;20: 6-19
2. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989;50:322-8
3. Karl E Miller, Koro CE. An assessment of the independent effect of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-6
4. Stahl SM. Dopamine system stabilizers, Aripiprazole, and the next generation of antipsychotic, part-2, Illustrating their mechanism of action. J Clin Psychiatry 2001;62:12
5. Marder SR, Mcqquade RD, Stock E, Marder SR, Macquade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia; safety and tolerability in short term, placebo controlled trials. Schizophr Res 2003;61: 123-26
6. Stanford M, Keating GM. Aripiprazole: in adolescents with schizophrenia. Paediatr Drugs 2007;9:419-23
7. Kern RS, Green MF, Cornbalatt BA. Neurocognitive effects of aripiprazole an open label comparison with olanzapine. J Psychopharmacol 2006;187:312-20
8. Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, et al. A prospective multicenter randomized parallelgroup, open label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006;84:77-89
9. Findling RL, Robb A, Nyilas M, Forbes RA. A multiplecenter, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008;165:1432-41
10. McEvoy JP, Daniel DG, Carson WH Jr, McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the effi cacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007;41:895-905
11. Sarin A, Nagpal J, Bohra NK, Jiloha RC, Rao GP, Sharma SK, et al. Open labeled, randomized, switch-over study of two fi xed dose (10/15 mg) of aripirazole: to evaluate the safety and effi cacy in the treatment of indian patients of schizophrenia. Indian J Psychiatry 2004;46:64-71
12. Chavda RK, Laxmi L, Nair BS, Ganndewar K. Effi cacy and tolerability of aripiprazole in patients with schizophrenia and schizoaffective disorders. Indian J Psychiatry 2004;46:150-55
13. Mcquade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. A Comparison of weight change during treatment with olanzapine or aripiprazole: result from a randomized, double blind study. J Clin Psychiatry 2004;65:47-56
14. Kinon, BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki. Olanzapine Versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol 2008;28:601-7
15. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90
16. Tandon R, Jibson MD. Comparing effi cacy of fi rst line antipsychotics: No evidence of differential effi cacy between risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole. Int J Psychiatry Clin Pract 2005;9:204-12
17. Kane JM, Meltzer HY, Carson WH, Mcquade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68:213-23
18. Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerseliaers W, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008;69:1046-56
19. Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double blinded, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2008;65:510-7
20. Kane JM, Osunttokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, Breier A. A 28 week, randomized, doubleblind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009;70:572-81
21. World Health Organization. The ICD 10 Classifi cation of Mental and Behavioural Disorder, Clinical Description and Diagnostic Guidelines. Geneva: WHO; 1992
22. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
23. Kay SR, Opler LA, Fiszbein A. A Positive and Negative Syndrome Scale (PANSS) Manual. Toranto, Ontario, Canada: MultiHealth Systems; 1992
24. Lingiaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale, a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100
25. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;45:11-19
26. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-21
27. L' I talien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 2007;68:1510-6
28. Kerwin R, Millet B, Herman E, Bankey CM, Lubin H, Pans M. et al. A multicentre, randomized, naturalistic, openlabel study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole (STAR) study. Eur Psychiatry 2007;22:433-43
29. Chrzanowski WK, Mcquade RD. Effectiveness of long termaripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia; a 52 week, open label comparison with olanzapine. Psychopharmacology 2006;189:259-66
30. Limosin F, Azorin JM, Krabs MO, Millet B, Glikman J, Camus V, et al. Present data and treatment schedule of aripiprazole in the treatment of schizophrenia. Encephale 2008;34:82-92
31. Raj L, Mangla D. Aripiprazole induced severe parkinsonian symptoms-A case report. Indian J Psychiatry 2004; 46:174-75